Join our newsletter
Get updated info, tips and news about breastfeeding, e-lactancia project and other initiatives from APILAM
Legitimation: Consent of the interested party
As a user and interested I inform you that the data you provide will be located on the servers of MailChimp (email marketing provider of APILAM) outside the EU in the USA. MailChimp is covered by the EU-US Privacy Shield agreement, whose information is available here, approved by the European Committee for Data Protection. See Mailchimp's privacy policy. (https://mailchimp.com/legal/privacy/).
The fact that you do not enter the personal data that appear on the form as mandatory may have the consequence that we can not meet your request.
You can exercise your rights of access, rectification, limitation and delete the data in apilam.es@gmail.com as well as the right to file a claim with a control authority.
You can consult the additional and detailed information on Data Protection on this website: http://e-lactancia.org, as well as consult our own privacy policy.
Barbiturate with general properties similar to those of amobarbital. Hypnotic and sedative.
It is used to treat pain in preparations combined with paracetamol or caffeine.
Discontinued medication due to risk of overdose and abuse (Suddock 2020).
At the date of the last update, there was no available published data on its excretion in breast milk.
Its pharmacokinetic data (low molecular weight, low protein binding, prolonged half-life) make it probable that it will pass to milk in an amount that could be significant.
A 7-day-old newborn, whose mother was taking a butalbital (50 mg) -paracetamol-caffeine compound four times a day, presented sedation, lethargy, hypotonia, insufficient feeding and vomiting. The infant had butalbital levels in its urine(Vohra 2019).
Known safer alternatives are preferable during lactation, especially during the neonatal period and in the case of prematurity (Burch 2020 and 2019, Worthington 2013).